872063-57-5
872063-57-5
Chemical Structure
Atesidorsen
Synonym(s): COR-004; ATL1103; ISIS 227452
- CAS No.: 872063-57-5
- Formula:N/A
- Molecular Weight:7164.00
SMILES: [Atesidorsen]
Biological Activity: Atesidorsen (COR-004, ATL1103) is an antisense oligonucleotide targeting the growth hormone receptor (GHR). Atesidorsen binds to GHR mRNA, inhibits human GHR translation, and reduces GHR synthesis through RNase H degradation. Atesidorsen reduces hepatic GHR mRNA and serum IGF-I. Atesidorsen can be used in research related to acromegaly[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Atesidorsen | Atesidorsen (COR-004, ATL1103) is an antisense oligonucleotide targeting the growth hormone receptor (GHR). Atesidorsen binds to GHR mRNA, inhibits human GHR translation, and reduces GHR synthesis through RNase H degradation. Atesidorsen reduces hepatic GHR mRNA and serum IGF-I. Atesidorsen can be used in research related to acromegaly. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Golounina O, et al. Pathogenetic therapeutic approaches for endocrine diseases based on antisense oligonucleotides and RNA-interference. Frontiers in endocrinology. 2025;16:1525373.
- [2]. Trainer PJ, et al. A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. European Journal of Endocrinology. 2018 Aug;179(2):97-108. [Content Brief]
- [3]. Kasuki L, et al. Innovative therapeutics in acromegaly. Best Practice & Research Clinical Endocrinology & Metabolism. 2022 Dec 1;36(6):101679.
